BackSOPHiA Genetics SA Overview

SOPHiA Genetics SA Receivables

Latest receivables for SOPH: $14M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$14.31M
33.82% YoYΔ $3.62M vs prior year quarter

Peer average

Loading

SOPHiA Genetics SA Receivables History

Loading

SOPHiA Genetics SA vs. peers: Receivables Comparison

Loading

SOPHiA Genetics SA Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SOPHiA Genetics SA (SOPH) FAQ

As of the most recent data (March 2026), SOPH shows a receivables of $14M. That compares with $11M in the prior-year period — up 33.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SOPH's receivables is now $14M (was $11M) — a 33.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SOPHiA Genetics SA is outperforming or lagging.

Tracking SOPH's receivables over time shows whether SOPHiA Genetics SA is scaling, shrinking, or reshaping that part of the business. The current reading is $14M That compares with $11M in the prior-year period — up 33.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has SOPHiA Genetics SA's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $14M) with ownership activity and broader fundamentals.

SOPHiA Genetics SA's receivables is $14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.